Clovis Oncology Inc (NASDAQ:CLVS) was a big mover last session as the company saw its shares surge 16% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company, as the stock is now trading above the volatile price range of $47.83 to $54.91 in the past one-month time frame. Clovis Oncology Inc (NASDAQ:CLVS) shares fell -5.55% in last trading session and ended the day on $55.96. CLVS return on assets is -22.30%. Clovis Oncology Inc (NASDAQ:CLVS) quarterly performance is -17.26%.
NewLink Genetics Corp (NASDAQ:NLNK) announced presentations highlighting its HyperAcute® and IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor programs at the upcoming American Society of Clinical Oncology (ASCO) 50th Annual meeting, May 30-June 3, 2014 in Chicago, IL. NewLink Genetics Corp (NASDAQ:NLNK) weekly performance is -12.17%. On last trading day company shares ended up $21.00. Analysts mean target price for the company is $38.17. NewLink Genetics Corp (NASDAQ:NLNK) distance from 50-day simple moving average (SMA50) is -17.17%.
Echo Therapeutics Inc (NASDAQ:ECTE) announced that it has mailed a letter to stockholders. Echo’s letter highlights, among other things, the stark difference between Echo’s highly qualified and experienced nominee, Robert F. Doman, who has extensive experience in the medical device and pharmaceutical industries, and the Platinum Group’s nominee, Shepard M. Goldberg, who has spent the majority of his career in the pool supply business. As previously announced, the Platinum Group is a dissident stockholder group led by Platinum Management that is pursuing a proxy contest to elect Shepard M. Goldberg to the Echo Board at Echo’s 2014 Annual Meeting of Stockholders to be held on Thursday, June 19, at 10:00 a.m., local time, at Echo’s offices located at 10 Forge Parkway, Franklin, Massachusetts 02038. The record date for determining those stockholders eligible to receive notice of, and to vote at, the 2014 Annual Meeting is May 13. Echo Therapeutics Inc (NASDAQ:ECTE) shares fell -6.18% in last trading session and ended the day on $1.67. ECTE return on assets is -86.70%. Echo Therapeutics Inc (NASDAQ:ECTE) quarterly performance is -46.13%.
Uroplasty, Inc. (NASDAQ:UPI) reported financial results for the fiscal 2014 fourth quarter and full year ended March 31, 2014. Global revenue from the Company’s Urgent® PC Neuromodulation System grew 34% to $4.1 million, as compared to $3.1 million in the fourth quarter of the prior year. Sales of Urgent PC in the U.S. were up 27% in the fourth quarter while sales of Urgent PC in international markets were up 74%. Uroplasty, Inc. (NASDAQ:UPI) ended the last trading day at $2.97. Company weekly volatility is calculated as 7.60% and price to cash ratio as 5.06. Uroplasty, Inc. (NASDAQ:UPI) showed a negative weekly performance of -9.73%.
Trevena Inc (NASDAQ:TRVN) announced the appointment of John M. Limongelli, Esq., to the newly created position of Senior Vice President, General Counsel & Corporate Secretary, effective immediately. Trevena Inc (NASDAQ:TRVN) shares moved down -7.08% in last trading session and was closed at $4.46, while trading in range of $4.41 – $4.78. Trevena Inc (NASDAQ:TRVN) year to date (YTD) performance is -31.38%.